adminOperator
Good day, everyone, and welcome to the Aytu Biopharma Fiscal 2026 Second Quarter Earnings Call. [Operator Instructions]
It is now my pleasure to hand the floor over to your host, Robert Blum. Sir, the floor is yours.
Robert Blum
Lytham Partners, LLC
All right. Thank you very much, and good afternoon, everyone. As the operator indicated, during today’s call, we will be discussing Aytu Biopharma’s fiscal 2026 second quarter operational and financial results for the period ended December 31, 2025. Joining us on today’s call is Aytu’s Chief Executive Officer, Josh Disbrow; and Ryan Selhorn, the company’s Chief Financial Officer. At the conclusion of today’s prepared remarks, we will open the call for a question-and-answer session. I’d like to remind everyone that today’s call is being recorded. A replay of today’s call will be available by using the telephone numbers and conference ID provided in the press release issued earlier today or by utilizing the link on the company’s website under Events and Presentations.
Finally, I’d also like to call to your attention to the customary safe harbor disclosure regarding forward-looking information. The conference call today will contain certain forward-looking statements, including statements regarding the goals, strategies, beliefs, expectations, and future potential operating results of Aytu Biopharma. Although management believes these statements are reasonable based on estimates, assumptions, and projections as of today, these statements are not guarantees of future performance. Time-sensitive information may no longer be accurate at the time of any telephonic or
Read the full article here
